<DOC>
	<DOCNO>NCT00732940</DOCNO>
	<brief_summary>The purpose study test safety tolerability repeat subcutaneous ( SC ) dose belimumab subject SLE .</brief_summary>
	<brief_title>Phase 2 Study Belimumab Administered Subcutaneously Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>This clinical trial evaluate safety , pharmacokinetics ( PK ) , effect biomarkers repeat subcutaneous ( SC ) administration belimumab subject SLE . As data permit , exploratory pharmacodynamic analysis perform evaluate correlation belimumab serum exposure , PGA , SELENA SELDAI , biomarker effect .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Clinical diagnosis SLE American College Rheumatology ( ACR ) criterion Active SLE disease On stable SLE treatment regimen Pregnant nursing Have receive treatment B cell target therapy Have receive treatment biologic investigational agent past year Have receive intravenous ( IV ) cyclophosphamide within 180 day Day 0 Have severe lupus kidney disease Have active central nervous system ( CNS ) lupus Have require management acute chronic infection past 60 day Have current drug alcohol abuse dependence within past year Have historically positive test test positive screening human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Have history allergic anaphylactic reaction drug , food , insects require medical intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Belimumab</keyword>
</DOC>